Gynecologic manifestations of hereditary nonpolyposis colorectal cancer: From inherited to sporadic disease

ONCOLOGY

Volumn 20, Issue 1, 2006, Pages 85-94

  Taylor, Nicholas ^a   Mutch, David G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA;

AUTOSOMAL DOMINANT DISORDER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; COLON RESECTION; COLORECTAL CANCER; ENDOMETRIUM CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; MISMATCH REPAIR; MLH1 GENE; MOLECULAR BIOLOGY; MSH2 GENE; NONHUMAN; OVARY CANCER; REVIEW; COLORECTAL TUMOR; DNA REPAIR; ENDOMETRIUM TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUTATION; OVARY TUMOR;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 33745909420     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Warthin A: Heredity with reference to carcinoma. Arch Intern Med 12:546-555, 1913.
2. Mecklin JP, Jarvinen HJ: Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 68:1109-1112, 1991.
3. Aarnio M, Mecklin JP, Aaltonen LA, et al: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64:430-433, 1995.
4. Aaltonen LA, Salovaara R, Kristo P, et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481-1487, 1998.
5. Chadwick RB, Pyatt RE, Niemann TH, et al: Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. J Med Genet 38:461-466, 2001.
6. Banno K, Susumu N, Yanokura M, et al: Association of HNPCC and endometrial cancers. Int J Clin Oncol 9:262-269, 2004.
7. Dunlop MG, Farrington SM, Carothers AD, et al: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105-110, 1997.
8. Liu B, Parsons R, Papadopoulos N, et al: Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2:169-174, 1996.
9. Nystrom-Lahti M, Wu Y, Moisio AL, et al: DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 5:763-769, 1996.
10. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396:643-649, 1998.
11. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079, 1991.
12. Parsons R, Li GM, Longley MJ, et al: Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75:1227-1236, 1993.
13. Boland CR, Thibodeau SN, Hamilton SR, et al: A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998.
14. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218, 1999.
15. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677-685, 1993.
16. Watson P, Vasen HF, Mecklin JP, et al: The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96:516-520, 1994.
17. Vasen HFA, Johan G, Offerhaus A, et al: The tumour spectrum in hereditary non-polyposis colorectal cancer: A study of 24 kindreds in the Netherlands. Int J Cancer 46:31-34, 1990.
18. Li GM and Modrich P: Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci U S A 92:1950-1954, 1995.
19. de Wind N, Dekker M, Berns A, et al: Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82:321-330, 1995.
20. Edelmann W, Yang K, Umar A, et al: Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91:467-477, 1997.
21. Jiricny J: Mediating mismatch repair. Nat Genet 24:6-8, 2000.
22. Gurin CC, Federici MG, Kang L, et al: Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 59:462-466, 1999.
23. Cohn DE, Basil JB, Venegoni AR, et al: Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 79:101-106, 2000.
24. Vassileva V, Millar A, Briollais L, et al: Apoptotic and growth regulatory genes as mutational targets in mismatch repair deficient endometrioid adenocarcinomas of young patients. Oncol Rep 11:931-937, 2004.
25. Zhou XP, Kuismanen S, Nystrom-Lahti M, et al: Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 11:445-450, 2002.
26. Vassileva V, Millar A, Briollais L, et al: Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 62:4095-4099, 2002.
27. Fishel R: The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: Revising the mutator hypothesis. Cancer Res 61:7369-7374, 2001.
28. Zhang H, Richards B, Wilson T, et al: Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 59:3021-3027, 1999.
29. Katabuchi H, van Rees B, Lambers AR, et al: Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55:5556-5560, 1995.
30. Kobayashi K, Matsushima M, Koi S, et al: Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn J Cancer Res 87:141-145, 1996.
31. Lim PC, Tester D, Cliby W, et al: Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability. Clin Cancer Res 2:1907-1911, 1996.
32. Kowalski LD, Mutch DG, Herzog TJ, et al: Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+endometrial cancers. Genes Chromosomes Cancer 18:219-227, 1997.
33. Esteller M, Levine R, Baylin SB, et al: MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 16:2413-2417, 1998.
34. Goodfellow PJ, Buttin BM, Herzog TJ, et al: Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 100:5908-5913, 2003.
35. Simpkins SB, Bocker T, Swisher EM, et al: MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 8:661-666, 1999.
36. Sumoi R, Hakala-Ala-Pietila T, Leminen A, et al: Hereditary aspects of endometrial adenocarcinoma. Int J Cancer 62:132-137, 1995.
37. Wijnen J, De Leeuw W, Vasen H, et al: Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 23:142-144, 1999.
38. Miyaki M, Konishi M, Tanaka K, et al: Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 17:271-272, 1997.
39. Hendriks YM, Wagner A, Morreau H, et al: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127:17-25, 2004.
40. Gruber SB, Thompson WD: A population-based study of endometrial cancer and familial risk in younger women: Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 5:411-417, 1996.
41. Millar AL, Pal T, Madlensky L, et al: Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet 9:823-829, 1999.
42. Whelan A, Babb S, Mutch D, et al: MSI in endometrial carcinoma: Absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer 99:697-704, 2002.
43. Pal T, Flanders T, Mitchell-Lehman M, et al: Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet 35:978-984, 1998.
44. Buttin BM, Powell MA, Mutch DG, et al: Increased risk for HNPCC-associated synchronous and metachronous malignancies in patients with MSI-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 10:481-490, 2004.
45. Jarvinen HJ, Aarnio M, Mustonen H, et al: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834, 2000.
46. Boks DE, Trujillo AP, Voogd AC, et al: Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 102:198-200, 2002.
47. Caduff RF, Johnston CM, Svoboda-Newman SM, et al: Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148:1671-1678, 1996.
48. MacDonald ND, Salvesen HB, Ryan A, et al: Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 60:1750-1752, 2000.
49. Maxwell GL, Risinger JI, Alvarez AA, et al: Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 97:417-422, 2001.
50. Basil JB, Goodfellow PJ, Rader JS, et al: Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 89:1758-1764, 2000.
51. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001.
52. Orth K, Hung J, Gazdar A, et al: Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci U S A 91:9495-9499, 1994.
53. Geisler JP, Goodheart MJ, Sood AK, et al: Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98:2199-2206, 2003.
54. Stratton JF, Thompson D, Bobrow L, et al: The genetic epidemiology of early-onset epithelial ovarian cancer: A population-based study. Am J Hum Genet 65:1725-1732, 1999.
55. Shannon C, Kirk J, Barnetson R, et al: Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res 9:1387-1392, 2003.
56. Arzimanoglou, II, Lallas T, Osborne M, et al: Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 17:1799-1804, 1996.
57. Rubin SC, Benjamin I, Behbakht K, et al: Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. N Engl J Med 335:1413-1416, 1996.
58. Watson P, Butzow R, Lynch HT, et al: The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82:223-228, 2001.
59. Brown R, Hirst GL, Gallagher WM, et al: hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15:45-52, 1997.
60. Strathdee G, MacKean MJ, Illand M, et al: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335-2341, 1999.
61. Gifford G, Paul J, Vasey PA, et al: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10:4420-4426, 2004.
62. Levin B, Ludwig KA, Steinbach G, for the National Comprehensive Cancer Network Colorectal Screening Panel: Colorectal Screening: Practice Guidelines in Oncology, v. 1.2005.
63. Risinger JI, Berchuck A, Kohler MF, et al: Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:5100-5103, 1993.
64. Berends MJ, Hollema H, Wu Y, et al: MLH1 and MSH2 protein expression as a prescreening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. Int J Cancer 92:398-403, 2001.
65. Berends MJ, Wu Y, Sijmons RH, et al: Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 21:4364-4370, 2003.
66. Halbert CH, Lynch H, Lynch J, et al: Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 164:1881-1887, 2004.
67. Hadley DW, Jenkins JF, Dimond E, et al: Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 22:39-44, 2004.
68. Hall MA, Rich SS: Laws restricting health insurers' use of genetic information: Impact on genetic discrimination. Am J Hum Genet 66:293-307, 2000.
69. Stephenson J: Genetic test information fears unfounded. JAMA 282:2197-2198, 1999.
70. Dove-Edwin I, Boks D, Goff S, et al: The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94:1708-1712, 2002.
71. Rijcken FE, Mourits MJ, Kleibeuker JH, et al: Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91:74-80, 2003.
72. Syngal S, Weeks JC, Schrag D, et al: Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129:787-796, 1998.
73. Annie Yu HJ, Lin KM, Ota DM, et al: Hereditary nonpolyposis colorectal cancer: Preventive management. Cancer Treat Rev 29:461-470, 2003.
74. Ruschoff J, Wallinger S, Dietmaier W, et al: Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A 95:11301-11306, 1998.
75. Lu K: Endometrial cancer in women with HNPCC. Future challenges in clinical and translational research for endometrial cancer (abstract). Int J Gynecol Cancer 15(2):400-401, 2005.
76. Syngal S, Fox EA, Eng C, et al: Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641-645, 2000.
77. Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277:915-919, 1997.
78. Vasen HF, Mecklin JP, Khan PM, et al: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424-425, 1991.
79. Bellacosa A, Genuardi M, Anti M, et al: Hereditary nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and counseling aspects. Am J Med Genet 62:353-364, 1996.
80. Vasen HFA, Watson P, Mecklin J-P, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453-1456, 1999.
81. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al: A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758-1761, 1997.